挪威与瑞典SARS-CoV-2疫苗接种后肌炎风险研究
结果显示mRNA疫苗调整IRR为0.84(95%CI 0.63-1.11),腺病毒载体疫苗为1.31(0.72-2.36),未观察到SARS-CoV-2疫苗接种后肌炎风险增加。
要点
- mRNA疫苗180天内调整IRR为0.84(95%CI 0.63-1.11),与未接种期相比无风险增加迹象。
- 腺病毒载体疫苗180天内调整IRR为1.31(95%CI 0.72-2.36),与未接种期相比无风险增加迹象。
- mRNA疫苗第一、第二、第三剂各自估计值与所有剂次合并估计值相似。
研究设计与样本
- 随访至肌炎 Incident 诊断、删失或研究结束(2023年5月21日)。
- 采用泊松回归估计发病率比(IRR)及95%CI,比较接种后风险期(每剂第0天至第180天)与未接种期的发生率。
- 通过调整性别、年龄、职业(医护人员)、地区、COVID-19检测阳性及合并症校正潜在混杂。
主要发现
- 未接种人年7 002 398中观察到101例肌炎事件。
- 任何mRNA疫苗组合接种后180天内,6 241 529人年中观察到99例肌炎事件。
- 腺病毒载体疫苗接种后180天内,445 256人年中观察到13例肌炎事件。
- 与未接种期相比,任何mRNA疫苗组合接种后180天风险期的调整IRR为0.84(95%CI 0.63-1.11)。
- 与未接种期相比,腺病毒载体疫苗接种后180天风险期的调整IRR为1.31(95%CI 0.72-2.36)。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to characterize the risk of myositis after Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination with messenger ribonucleic acid (mRNA) or adenoviral vector vaccines. METHODS: We conducted a population-based cohort study in Norway and Sweden of 13 million persons who turned 12 years or older in 2021 and were residents at the start of follow-up on 27 December 2020. The participants were followed until incident diagnosis of myositis, censoring, or the end of the study (21 May 2023). We used Poisson regression to estimate incidence rate ratios (IRRs) with 95% CIs, comparing rates in risk periods (day 0 up to and including day 180 after each dose) with rates in unvaccinated periods. Corrections for potential confounding were made by adjusting for sex, age, occupation (health-care worker), region, positive COVID-19 test, and comorbidities. RESULTS: We observed 101 myositis events in 7 002 398 unvaccinated person-years and 99 myositis events within 180 days of any combination of mRNA vaccines (6 241 529 person-years), and 13 with the adenoviral vector vaccine (445 256 person-years). The adjusted IRRs for the 180-day risk periods following any combination of mRNA vaccines and the adenoviral vector vaccine were 0.84 (95% CI, 0.63-1.11) and 1.31 (0.72-2.36), respectively, compared with unvaccinated periods. The estimates for each specific first, second and third dose of mRNA were similar to the estimate of all doses combined. CONCLUSION: In this nationwide study of >13.6 million person-years in two countries, there were no signs of an increased risk of myositis after SARS-CoV-2 vaccination, neither after the mRNA vaccines nor after the adenoviral vector vaccine.
引用
- Ljung R, Pihlström N, Dahl J, et al. SARS-CoV-2 vaccination and myositis in Norway and Sweden. Rheumatology (Oxford). 2026. PMID: 41273774. doi:10.1093/rheumatology/keaf609
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。